$AGIO News

Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?

Agios Pharmaceuticals (AGIO) Could Be 28% Undervalued Following Its November Results Call Date

Agios Pharmaceuticals (AGIO) Stock Looks Fully Priced Against Current Sales

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37

B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50

Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel

JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34

Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52

Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39

Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...

HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55

Agios Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Agios Pharmaceuticals Q2 Earnings Call Highlights

Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript

Agios Pharmaceuticals (NASDAQ:AGIO) Surges on Q2 Revenue Beat Driven by PYRUKYND Sales

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

Agios Pharmaceuticals Q2 EPS $(1.69) Misses $(1.67) Estimate, Sales $44.745M Beat $25.521M Estimate

Tebapivat Sickle Cell Setback and Mitapivat Priority Review Could Be A Game Changer For Agios (AGIO)

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release